EASME

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Vital Beats is a developer of a medical platform focused on providing clinical decision support for the remote care of heart patients with pacemakers. The platform employs machine learning and participatory design principles, combined with advanced analytics, to continuously monitor cardiac devices. By utilizing a patent-pending technique, it triages patients effectively, allowing for timely interventions. This approach enhances the management of chronic conditions, ensuring that patients benefit from digital healthcare solutions that monitor their implanted devices around the clock. Vital Beats emphasizes user experience by integrating Nordic aesthetics into its platform, making it both enjoyable and valuable for users.

Nuada is a company based in Braga, Portugal, specializing in the development of innovative systems that enhance hand function. Its products are designed to improve performance in healthcare, sports, and various professional activities. Nuada's solutions feature lightweight, breathable, and flexible smart textiles that can be customized to meet individual needs. The technology is non-intrusive and aims to be an essential everyday wearable, providing users with a seamless experience that they may even forget they are wearing.

Limbic is a London-based company that specializes in mental healthcare technology. Founded in 2017, it develops a software development kit (SDK) that leverages machine learning to analyze heart rate data collected from wearable devices like the Apple Watch, allowing for the assessment of users' emotional states. Limbic also offers psychological therapies for adults, focusing on improving mental health through innovative solutions. Its platform supports healthcare professionals by providing tools for stress detection and facilitating clinical assessments, thereby enhancing the efficacy of psychological therapy. By combining AI technology with wearable devices, Limbic aims to address the growing challenges in mental health care and improve patient outcomes.

Pre Diagnostics is an innovative Norwegian diagnostic company that seeks to create value for patients, partners, and investors by developing pioneering and patient-friendly, in-vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept is built upon the scientific premise that a disease evokes systemic responses in macrophages unique to that disease which can be accurately measured in the blood samples of patients. Pre Diagnostics aims to be a leader in the diagnosis of early Alzheimer’s disease and is thus focused on the development of IVD biomarker products that use well-established technologies and procedures.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

ChemoTech is a Scandinavian company based at Medicon Village in Lund, Sweden. The company’s founders have extensive experience of cancer treatment through surgical oncology and clinical development. The company is dedicated to using its unique patented know-how to develop innovation in cancer care through genuine research and clinical trials.

Double Bond Pharmaceutical is a pharmaceutical company focused on developing and commercializing innovative treatments for cancers, infections, autoimmune diseases, and other life-threatening conditions. The company aims to address unmet medical needs by providing more efficient and safer therapeutic options for patients. Through its first-in-class approaches, Double Bond Pharmaceutical seeks to improve patient outcomes and contribute significantly to the healthcare market.

Vetherapy is a biotech company established in 2015, specializing in veterinary regenerative medicine and tissue engineering. The company develops innovative products utilizing stem cells, platelet-rich plasma (PRP), and biomaterials to address various animal health conditions. Vetherapy focuses on ensuring quality and safety in the processes of stem cell isolation, expansion, and cryopreservation, as well as in the extraction of plasma rich in growth factors. By providing access to a stem cell and PRP bank through their cryopreservation services, Vetherapy ensures that these vital therapeutics are readily available for immediate veterinary use. Their therapies promote tissue regeneration, enhance overall physical condition, and facilitate faster healing in animals, addressing a range of clinical needs effectively.

PlumeSTARS is an innovative PMI specialized in drug delivery to lung for the treatment of respiratory diseases.

Mecwins specializes in developing advanced nanomechanical sensing technology to create sensitive immunoassays aimed at improving healthcare outcomes for individuals at risk for oncology, cardiovascular diseases, and infectious diseases. Their innovative platform combines nanomechanical sensing with plasmonic emission using a sandwich immunoassay approach, allowing for the production of ultrasensitive detection systems. This technology enables researchers to achieve enhanced sensitivity in disease detection, ultimately contributing to better diagnostics and treatment options in critical areas of healthcare.

KronosDNA Srl is a young biomedical company specialized in the reproductive genetics and founded by a team of women, researchers with technical-scientific and managerial expertise. KronosDNA is committed to improving maternal and new born healthcare and facilitating advances in laboratory medicine thanks to the development, prototypization and validation of diagnostic tools to support professionals in the reproductive medicine field.

TomoWave commercializes and produces innovative imaging modalities with applications in clinical medicine and preclinical research. Our proprietary technology “listens to the sound of light” to produce highly resolved images from the depth of tissues. The main targeted medical needs of TomoWave platform technology include detection and diagnostics of cancer, image guided interventions and monitoring the effectiveness of anticancer therapy and diagnostics imaging of vascular and blood related conditions. A pipeline of innovative optoacoustic and laser ultrasonic imaging technologies based on inventions made by the company founder, Dr. Alexander Oraevsky, pioneer of biomedical optoacoustics and recipient of multiple grants and awards for development of molecular imaging systems and applications. TomoWave Laboratories has the capability to generate intellectual property and develop its IP from idea to validated clinical prototypes and brings these technologies to the market place through regulatory certification.

Allergy Data Laboratories continues to manage and support the Allergome project.

Gedea Biotech AB, founded in 2015 and based in Lund, Sweden, focuses on developing an antibiotic-free treatment for vaginal fungal infections, a common issue affecting approximately 75% of women at some point in their lives. The company's key product, GA101, utilizes natural substances to lower vaginal pH, provide physical barrier protection, and inhibit biofilm formation. This innovative approach aims to offer a safe and effective solution for treating and preventing vaginal infections without the use of antibiotics. Gedea Biotech is committed to addressing women's health needs through its unique treatment options.

Taliaz is revolutionizing the treatment and management of mental health disorders with PREDICTIX. PREDICTIX is a CE registered product that provides an advanced decision support software for psychiatrists and general practitioners. Harnessing artificial intelligence (AI), PREDICTIX can enable easy, effective and rapid patient assessment, improved prescribing precision and management for a wide range of mental health conditions. PREDICTIX understands that mental health disorders are multifaceted and unique. Combining data science with machine learning, PREDICTIX translates complex genetic, metabolic, demographic and clinical data into an easy-to-use assessment and prescribing support tool. Starting in the field of depression where the right antidepressant is only prescribed in 49% of cases (Chekroud et al., 2016), PREDICTIX improves treatment prescribing accuracy by 47% to achieve 72% prescribing accuracy*. PREDICTIX PRODUCTS - PREDICTIX Digital – 30% improvement in prescribing accuracy*. Combines AI analysis of patients’ clinical and demographic data to support doctor prescribing decisions. - PREDICTIX Genetics – 47% improvement in prescribing accuracy*. Further optimizes treatment decisions by combining a patient’s DNA analysis with AI. PREDICTIX is an ideal software solution for payors, providers, DNA laboratories and telemedicine providers to improve patient outcomes, reduce costs and expand service offerings in the mental health space. PREDICTIX is commercially available in Europe. Learn more at predictix.ai. *Based on a retrospective analysis of four STAR*D study medications. STAR*D is one of the world’s largest prospective studies for optimal antidepressant administration. Disclaimer: Taliaz is developing the PREDICTIX Genetics and PREDICTIX Digital products. PREDICTIX (Genetics) Antidepressant is currently available for commercial use in the EU and Israel. Outside of the EU and Israel, PREDICTIX Genetics products are currently limited by law for investigational use only. PREDICTIX Digital products are currently limited by law for investigational use only.

Domalys SAS, established in 1990 and based in Vienne, France, specializes in providing innovative solutions and customized products aimed at enhancing the lives of elderly individuals and their caregivers. The company offers a range of products, including the Aladin lamp and telecare assistance, as well as tracking software and specialized tables designed for use in nursing homes. Domalys focuses on preventing falls and detecting early warning signs of health issues through intelligent lighting and technology that is co-designed with care staff. By addressing the specific needs of dependent elderly individuals, Domalys aims to improve their daily lives and the experiences of those who care for them.

Nateo Healthcare, founded in 2016 and based in Toulouse, France, specializes in designing, developing, and manufacturing medical devices for the fields of gynecology and obstetrics. The company focuses on creating innovative connected medical devices and software that enable healthcare professionals to monitor the health of expectant mothers and their unborn babies. Among its key products is a belt equipped with ultrasound probes that can assess fetal positions, measure the mother's heart rate, and monitor uterine contractions. Additionally, Nateo Healthcare is working on a new generation of mobile and connected fetal heart rate monitors, which facilitate both hospital and home fetal telemonitoring, allowing for enhanced patient self-monitoring and tailored healthcare interventions.

SensoGenic, Inc. develops innovative diagnostic biosensors specifically designed to detect food allergens. Founded in 2016 and based in Ness Ziona, Israel, the company offers portable, handheld analyzers that connect to a mobile application, allowing users to identify allergens without physical contact. This technology provides critical information for individuals with food allergies, enabling them to dine out safely and avoid allergic reactions. SensoGenic emphasizes understanding user needs to enhance the functionality and usability of its products, positioning itself as a leader in allergen detection solutions.

Scandion Oncology A/S is a biotechnology company based in Copenhagen, Denmark, focused on developing treatments for chemotherapy resistance in cancer patients. Founded in 2017, the company is advancing its lead product, SCO-101, which is currently undergoing Phase II clinical trials for breast and colorectal cancers. Additionally, it is working on SCO-201, a product in late pre-clinical development aimed at treating solid tumors. Scandion Oncology collaborates with the University of Copenhagen to co-develop SCO-301, a candidate designed to reverse drug resistance, and has partnered with Per Norlén to investigate the combined anti-tumor effects of mitazalimab and SCO-101 in resistant tumor models. The company's mission is to enhance treatment outcomes and quality of life for cancer patients who experience chemotherapy resistance, addressing a significant challenge in oncology where nearly half of patients do not respond to chemotherapy.

CSF-Dynamics is developing a new type of hydrocephalus shunt that overcomes the major issues of current shunts on the market. The shunt is currently undergoing clinical testing. CSF-Dynamics expects the shunt to be approved for clinical use by end of year 2021.

Cytox Limited specializes in developing products and services aimed at diagnosing and treating neurodegenerative disorders, particularly Alzheimer's disease. The company has created a genetic-based blood test that assesses the risk and diagnosis of Alzheimer's in its early stages, addressing a critical need as the prevalence of the disease rises globally. Cytox's offerings include cellular and genetic assays for identifying cell cycle deficits in patients, along with biomarker and drug-screening services for pharmaceutical companies engaged in clinical trials. The company collaborates with Affymetrix, part of Thermo Fisher Scientific, to enhance its commercial testing capabilities. Founded in 2004 and headquartered in Birmingham, United Kingdom, with additional offices in Manchester and Oxford, Cytox serves pharmaceutical and biotechnology firms, as well as research laboratories involved in clinical research and drug development.

Clarify Analytical is an innovative service providing start-up committed to develop state-of-the-art mass spectrometry based methodologies.

CMS Dental provides products and treatment concepts for the modulation of biofilm and for preventing infectious conditions of the oral cavity. In their field of endodontics, they developed root-filling systems. Their oral cavity is associated with the development of systemic chronic diseases including cardiovascular disease, alzheimer's, oral, pancreatic cancer, and arthritis.

Vetbiobank is a biotech company specializing in veterinary regenerative medicine. The company develops cell and tissue therapies aimed at enhancing animal health and care. In addition to its focus on veterinary applications, Vetbiobank also engages in human cellular and tissue therapies. It supplies veterinarians with clinical-grade cell and tissue products, thereby supporting medical and scientific needs within the veterinary field. Through its innovative approach, Vetbiobank aims to improve outcomes for animals by advancing regenerative medicine techniques.

Stokhos started as a scientific mathematical project named REPRO with the aim to reduce ambulance response times. The potential social impact motivated the foundation of Stokhos. We at Stokhos are all very enthusiastic about mathematics and science and are tirelessly working on making the world a safer place. As their products were first developed for he medical emergency market, we have a strong affinity with the medical emergency field. All members of their team, do, for example, have valid first aid certification.

OmniSpirant develops regenerative gene therapies with the potential to transform respiratory medicine.

Cellestia Biotech AG is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for cancer and immunological disorders. Founded in 2014 as a spin-off from the École Polytechnique Fédérale de Lausanne, the company is headquartered in Basel, Switzerland, with an additional location in Lausanne. Cellestia focuses on its lead compound, CB-103, which is a novel oral pan-NOTCH inhibitor targeting NOTCH-dependent leukemia, lymphoma, and solid tumors. The drug has successfully advanced to Phase 2 clinical trials for patients with multi-drug resistant cancers. In addition to CB-103, Cellestia is developing a pipeline of novel transcription factor inhibitors and NOTCH-specific biomarkers to enhance patient selection and treatment outcomes. The company's approach aims to control and modulate pathogenic gene expression through selective inhibition of transcription factors in the cell nucleus, contributing to integrated drug and personalized medicine development.

Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

CMI NOV is a healthcare company provides solution for mitral valve repair during open heart surgery.

Delta Diagnostics, founded in 2018 as a spin-off from TNO – The Netherlands Organisation for Applied Scientific Research, specializes in photonic biosensor technology. The company leverages patented innovations developed in TNO's Optics department to commercialize rapid, sensitive, and low-cost biosensors and instruments. These advanced biosensors utilize integrated photonics and optical chips containing waveguides that facilitate the transportation of light across multiple sensors. This technology enables real-time, label-free monitoring of biomarkers, allowing for accurate concentration measurements within minutes. Delta Diagnostics aims to enhance research in life sciences and facilitate the development of novel diagnostics through its innovative biosensing solutions.

Diabeloop is a medical device company based in Grenoble, France, focused on innovating diabetes treatment through advanced technology. Founded in 2015, the company specializes in developing an AI-based closed-loop system that automates insulin delivery for individuals with type 1 diabetes. This system includes a blood sugar monitoring device that combines a glucose sensor, an insulin pump, and a smartphone application featuring an embedded algorithm. By continuously measuring glucose levels and delivering the appropriate insulin dosage, Diabeloop aims to reduce the mental burden on patients, allowing them to manage their condition more effectively and live their lives with greater ease.

MyCol d.o.o. is women-owned start-up, founded in Mach 2017 by researchers from materials science, chemical and graphic technology, and environmental science. The group was gathered within the research on chromogenic materials at National Institute of Chemistry, Ljubljana, Slovenia. We aim to become highly competitive provider of innovative solutions for visual control of temperature and for registration of their changes in the past. In general, our product is a smart label with temperature-sensitive chromogenic material, printed in an arbitrary form which change colour if passing the defined temperature. The changes are seen by naked eye or registered by video camera, thus no electric supply or IT network is required. The products in MyCol’s portfolio are unique and have plenty of freedom on including design- and visual messages and assure control of different temperatures. With this we are able to assist in situations where overheating above the prescribed temperature should be noted in repeatable (reversible) or single (irreversible) way.

Raylytic develops the only fully integrated platform for automated medical image analysis and clinical data extraction. They develop UNITY, the only fully integrated software platform that streamlines the setup and conduct of clinical data collection tasks, including CRFs, PROMs and AI-based medical image analysis. UNITY is utilized to operate private registries, to conduct clinical trials for regulatory approval, post-market surveillance and general medical data collection tasks, providing the basis for evidence based medicine and the backing of product claims with documented, traceable scientific substantiation. Their modular framework utilizes algorithms from industrial and medical image processing as well as sophisticated machine learning algorithms, allowing for the first time the highly automated data extraction and quantification of endpoints based on medical images. The most recent addition is their Clinical Data Module, which seamlessly integrates the electronic capture of patient reported outcome measures (PROMs) into the clinical routine.

Biom'Up, expert in the field of resorbable biomaterials, designs, develops and manufactures unique medical devices based on collagen technology. These innovative and clinically proven products cover many different surgical specialties - orthopaedics, spinal, cardiac, general and maxillo-facial - and improve patient healing by allowing guided regeneration of soft tissues and bone.

EarWays Medical Ltd. is an innovative company focused on developing ear-care solutions aimed at improving the well-being of children and adults globally. The company specializes in a medical device designed for the effective removal of earwax, utilizing a patented technology that features a flexible, coated helical tip for easy navigation in the ear canal. This device is suitable for both clinicians and home users, facilitating the management and extraction of cerumen. Backed by a team of experts in bioengineering, medical devices, and ear health, EarWays Medical is well-positioned to address the medical demand for accessible and effective ear care, helping to prevent temporary hearing loss caused by earwax buildup.

Brainmarc Ltd. is a company based in Yokne'am, Israel, with an additional location in Hoboken, New Jersey, that specializes in developing a digital platform for cognitive remediation. Founded in 2013, the company utilizes its proprietary Brain Engagement Index (BEI) technology to measure brain engagement and mental activity through electroencephalography (EEG) sensors integrated into headsets. Brainmarc's platform offers therapeutic products aimed at addressing cognitive and mental disorders, demonstrating significant effectiveness in treating cognitive impairments. This technology has been validated through numerous patient cases in clinical settings across the United States, Canada, the European Union, and Israel, providing a reliable solution for measuring attention levels during cognitive exercises.

Vibrosonic GmbH is a company specializing in the development, production, and marketing of innovative hearing solutions tailored for individuals with varying degrees of hearing impairment. Originating as a spin-off from the Fraunhofer Project Group for Automation in Medicine and Biotechnology and the University ENT Clinic Tübingen, Vibrosonic focuses on creating discreet hearing devices that integrate advanced microsystem technologies. Their unique approach involves the use of piezoelectric principles to design hearing contact lenses that can be directly placed on the eardrum. This technology transmits sound through vibrations rather than traditional speakers, enhancing the auditory experience while minimizing discomfort for users. Through its specialized equipment, Vibrosonic aims to improve the quality of life for those affected by hearing loss.

Eden Microfluidics is a young innovative company founded in 2017. The company aims to provide advanced and certified materials, microfabrication and microfluidics solutions to both researchers and industrial partners. Eden Microfluidics is driven by a team of talented and passionate scientists, innovators and entrepreneurs, thriving to develop radical microfluidic solutions, for biomedical to environmental challenges. All together, they assemble a large IP portfolio of polymer and epoxy formulations, cellular micro-environment and microfluidic remediation systems. Eden Microfluidics is here to offer you access to the latest, up-to-date microfluidic science and technology.

Immundnz is an immunology CRO specialised in immune modelling, immune response and tissue damage analysis, in vivo and in vitro cell culture systems for preclinical drug research and development. We are different because we are experienced scientists who will design an experimental model and use customised assays as well as standard assays tailored for the right solution for your problem. We will develop novel assays in our laboratory to meet your specific and unconventional need.

Brain Stimulation AB is a Swedish SME started in 2011 with the aim to provide an efficient assessment and rehabilitation after stroke and traumatic brain injuries. Exploiting brain plasticity results from research within a new concept of rehabilitation and diagnosis of cognitive impairments and disability of attention in stroke patients (Spatial Neglect). They address the global challenge of rehabilitating need for cognitive and upper limb impairments from Stroke, Dementia, Traumatic Brain Injuries, Parkinson and other degenerative brain diseases by using Enriched Rehabilitation.

EpiGuard is a Norwegian company founded in 2015 by a group of doctors from Oslo University Hospital, alongside co-founders Inven2, Eker Group, and Hansen Protection. The company specializes in the development and manufacture of medical transportation systems designed to safely transfer patients with contagious diseases. EpiGuard's flagship product is a single-patient isolation and transport system that helps prevent the spread of infections to the environment and protects patients from contaminated surroundings. This innovation not only safeguards medical staff but also ensures that patients receive proper care during transport. With expertise spanning various medical fields, including intensive care and infectious diseases, EpiGuard aims to enhance safety and efficiency in patient transport.

FGen is a Swiss start-up company founded 2011 in Basel as a spin-off from the Department of Biosystems Science and Engineering of the ETH Zurich. As a contract reasearch organization we collaborate with partners from Biotech, Life Sciences, and Pharma in order to establish efficient bioprocesses and to develop new biopharmaceuticals.

Toleranzia develops drugs that utilize the immune system's own intrinsic power to treat autoimmune orphan diseases. The drugs, which target the disease cause, can cure or greatly alleviate the disease and not just reduce the symptoms that current treatments do. The company's drug candidate, TOL2, is developed for the autoimmune nerve and muscle disease myasthenia gravis.

Respinova specializes in the development of non-invasive devices for the treatment of respiratory disorders, particularly chronic obstructive pulmonary disease (COPD). The company's primary product, the PulseHaler, leverages innovative technology that generates dynamic air pressure pulses. These pulses travel quickly through the airways, creating momentary dilating forces that help open collapsed airways and facilitate mucus clearance. By smoothing and spreading the mucus lining within the airways, the PulseHaler aids in airway clearance and reduces the likelihood of airway re-collapse, providing a significant improvement in treatment options for COPD patients.

Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.

Hephaistos Pharma is a biotechnology company focused on advancing oncology treatments through innovative immunotherapy solutions. The firm develops a platform that utilizes active and non-specific immuno-stimulants to enhance the effectiveness of existing antibodies by transforming cold tumors into hot targets, which can significantly improve patient outcomes. This approach aims to address unmet medical needs in cancer treatment, enabling patients to tackle previously incurable cancers. Hephaistos Pharma is dedicated to elevating immunotherapy efficiency by stimulating immune responses, thereby offering new hope in the fight against cancer. Interested parties can access more information through an online inquiry form available on the company's website.

Cardioset Medical is a group of scientists and business people who strive to make a life-changing impact on patients suffering from heart failure lung edema. With over 15 years of research and development we now have the solution that can literally revolutionize millions of HF patients' lives by enabling them to self-monitor their lung edema state and detect small changes at an even earliest stage.

ODI Medical specializes in developing innovative technology for the bedside evaluation of circulatory failure through the assessment of microcirculation. The company's medical device streamlines the collection of microvascular data and has diverse clinical applications. These include monitoring patients on mechanical heart and lung machines, evaluating the toxicity of chemotherapy, and early detection of evolving sepsis. Additionally, the technology is useful for monitoring chronic wounds and conducting mass screenings for conditions such as Ebola, bird flu, and epidemic meningitis. By employing non-invasive techniques, ODI Medical enables healthcare professionals to enhance patient therapy through improved assessment of microcirculation.

Minnemera is a company based in Stockholm, Sweden, that specializes in developing digital cognitive screening tools. Founded in 2017, the company focuses on creating neurocognitive tests that automatically compare individual results with normative data and personal baseline values to identify abnormalities. This innovative approach aims to enhance the assessment of cognitive function and support healthcare professionals in diagnosing and monitoring cognitive health.

PreOmics GmbH, founded in 2016 and based in Planegg, Germany, specializes in mass spectrometry (MS)-based proteomics. The company develops innovative tools, including the iST Kit, designed for efficient sample preparation and peptide pre-fractionation, which allows researchers to process peptide mixtures in just one hour. PreOmics focuses on providing solutions for the identification of protein interaction partners, large-scale protein discovery, and quantification of proteins, as well as the analysis of post-translational modifications. As a spin-off from the Max-Planck Institute of Biochemistry, the company aims to enhance protein analysis for researchers worldwide by offering high-quality technologies that streamline and improve research outcomes.

RemAb Therapeutics is a developer of polymeric glycoconjugates molecule designed to remove antibodies and treat nosocomial infections. The company's technology aims to develop polymeric glycoconjugates to eliminate non-neutralizing natural antibodies that interfere with the natural response of the immune system and favor pathogen growth, providing patients with a new way of treating and preventing various pathologies.

Chemicare is a biotechnology company established in December 2016, focused on the discovery and development of orphan drugs for patients with calcium-related genetic diseases. The company aims to improve the quality of life for individuals suffering from conditions such as Tubular Aggregate Myopathy, York Platelet Syndrome, and Stormorken Syndrome. Chemicare is dedicated to creating therapies that address the abnormal intracellular calcium levels characteristic of these rare diseases, enabling healthcare professionals to provide effective treatment options for affected patients.

CardiacSense is an innovative start-up on track to revolutionize the Wearable Health Industry by providing affordable, comfortable FDA & CE certified Medical Watches and Wristbands capable of continuous, long term, ambulatory and non-invasive monitoring of life critical functions including Heart Rate, Pulse Rate, Respiratory Rate, Core Temperature, Oxygen Saturation and Blood Pressure. These capabilities enable accurate real time diagnostics of medical conditions such as Heart Arrhythmias (incl. Atrial Fibrillation), Hypertension, COPD, Heart Failure, Sleep Apnea and infections (such as COVID-19).

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Surgitate fabricates synthetic models that surgeons, medical and veterinary students, and other medical staff such as nurses and obstetricians can practice on. Their models are designed to create a realistic feel of incision, dissection, and suturing. Their cofounders are a materials engineer (Ozge Akbulut, PhD) and a thoracic surgeon (Barkın Eldem, MD). Surgitate has two investors: Farplas, leading plastic automotive parts manufacturer in Turkey, and Inovent, Turkey’s first technology commercialization/accelerator and seed funding company. They rely on expertise of Farplas in process development, molding, and painting for the mass scale production of synthetic body parts. Inovent assures that we are well-connected to our potential investors and customers; and handles business and marketing plans.

Segmentum Imaging is a brand new app allowing you to count samples more quickly than traditional methods have previously allowed, whilst releasing you from the confines of the lab. Do your work conveniently, increasing your output and decreasing your time spent on repetitive actions. The adoption of digital pathology has been increasing dramatically. It is being used for more convenient diagnosis, easier sharing of images between consultants, large-scale collection for research purposes and in the creation of online virtual archives, critical in teaching and multi-centre research. Whilst the tools for researchers to utilise digital images have become very advanced, they are often very expensive and are commonly based in individual laboratories. This can easily result in considerable bottlenecks in use and limitations of access often lead to these facilities being simultaneously very costly but under-utilised.

AFYX Therapeutics is changing the way mucosal diseases are treated. They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. Their proprietary Rivelin® patch is flexible, biodegradable, and adhesive to mucosal surfaces. Designed with electrospinning technology, it delivers a therapeutic directly to the site in need, without interfering with patients’ daily activities.

Mimetis Biomaterials SL is a Barcelona-based company that specializes in designing and manufacturing biomimetic bone graft substitutes for various medical applications, including dental, craniomaxillofacial, and orthopedic sectors. Founded in 2013, Mimetis focuses on creating synthetic solutions that closely mimic the properties of natural bone to address specific patient needs. The company offers a range of products, including biomimetic granules for filling bone defects, as well as services such as original equipment manufacturing, consulting, and co-development. With over 15 years of research backing its innovations, Mimetis has secured more than 2.5 million euros in public grants and funding to support its growth. The company is currently seeking additional funding to expand its commercial presence in orthopedics and to launch its advanced 3D-printed biomimetic solutions, aimed at improving patient outcomes in complex cases.

VisionHealth GmbH is a healthcare technology company based in Munich, Germany, founded in 2017. It specializes in creating software solutions for patients with various respiratory diseases, particularly those reliant on inhalers for conditions such as asthma and COPD. Its primary product, Kata, is a digital healthcare assistant that utilizes artificial intelligence and machine learning to improve inhalation therapy. The application facilitates effective inhaler use by providing training and support, helping patients avoid shortness of breath and reduce the need for hospital visits. By enhancing the management of chronic lung conditions, VisionHealth aims to lower therapy costs and improve the overall quality of life for patients.

Magentiq Eye Ltd. is a medical device company based in Haifa, Israel, established in 2014. It specializes in developing advanced technologies for endoscopic procedures, particularly focusing on automatic polyp detection during colonoscopies. The company's flagship product, the Automatic Polyp Detection System (APDS), leverages deep learning and computer vision to enhance the accuracy of polyp identification, thereby reducing the miss rate during examinations. The APDS is available in two formats: APDS-RT, which operates in real-time by processing video feeds from endoscopic cameras, and APDS-OFL, which analyzes pre-recorded colonoscopy videos. Given the prevalence of colonoscopies—approximately 40 million performed annually—the system aims to improve patient outcomes by increasing detection rates and minimizing the risk of interval cancers. Magentiq Eye's technology not only supports physicians in making more informed decisions during procedures but also has the potential for integration with existing endoscopic equipment or as a service model for clinics and hospitals.

Dytective is the scientifically validated reference tool for detection and improvement of skills related to dyslexia. Dytective combines two scientifically validated tools developed by Change Dyslexia. In only 15 minutes, through a series of tests, according to your age and abilities, Dytective Test detects if you are at risk of having dyslexia. With DytectiveU you will improve your reading and writing skills while having fun playing.

Deneb Medical is a start-up focused on creating a robotic platform intended for various surgical applications, including neurosurgery, cranio-maxillofacial surgery, head and neck surgery, urology, and general surgery. The company's technology centers around a laser-based robotic surgery system that assists surgeons, particularly in spine surgery, by utilizing optical and photonic techniques for tissue ablation. This innovative system enhances surgical precision and efficiency through features such as three-dimensional visualization and augmented reality guidance, ultimately aiming to facilitate minimally invasive procedures and improve patient outcomes.

Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.

Radiobotics focuses on developing advanced machine learning algorithms that assist healthcare professionals in the analysis of medical images, particularly x-rays of bones and joints. By automating the reading of these images, the company's technology streamlines routine tasks and enhances access to radiology reports. This innovation aims to improve diagnostic quality, supporting doctors in making informed medical decisions more efficiently.

Anima is a unique AI-based short-screening solution for early detection of children suffering from sexual abuse. The tool will screen and identify experience of sexual abuse at an early stage, thus prevent further abuse and providing treatment. This in turn will reduce future mental and physical negative consequences of the abuse.

Cambridge Mask Co specializes in the manufacture and distribution of high-performance consumer pollution masks that utilize advanced filter technology originally developed for military applications in chemical, nuclear, and biological warfare. Their masks are designed to filter nearly 100% of viruses, bacteria, gases, and particulate matter, providing effective protection against air pollution. Available in various sizes and patterns to accommodate families, these masks have gained recognition and are supplied to notable clients, including the United Nations and British Airways. The company's commitment to health and safety is reflected in its use of military-grade filtration technology, which incorporates activated carbon cloth to ensure optimal protection for users.

Picterus is developing a smartphone application aimed at diagnosing jaundice in newborns, a condition that contributes to over 100,000 deaths annually, particularly in impoverished areas of Sub-Saharan Africa and South Asia. Existing screening devices are prohibitively expensive, often costing around $7,000, which limits access in low-resource settings. The app utilizes patented biomedical optics technology to provide accurate estimates of jaundice levels while accounting for variations in skin pigmentation. This innovation addresses the growing need for affordable and effective diagnostic tools, especially given the trend of shorter hospital stays post-birth and the rising rates of jaundice-related hospital readmissions. By enabling parents to monitor their child's jaundice levels at home, Picterus aims to improve health outcomes for vulnerable populations.

E-Motion Medical Ltd was founded in 2011 by a pioneering multidisciplinary team with extensive experience in medicine, science, management and business. The E-Motion System™ delivers unique patterns of stimulation to the esophagus, thereby generating contractions, which restore natural function to the digestive system and promote motility throughout the gastrointestinal tract. The stimulation is applied to the esophagus using their proprietary E-Motion Tube™, which can also double as a feeding tube, and is easily placed in the same manner.

Sepsia Therapeutics is developing new broad-spectrum drug and cellular therapies against sepsis, a life-threatening condition caused by the host response to an infectious agent, mostly bacterial and fungal. Their strategies are based on the host’s scavenger-like receptors present on lymphocyte cell surfaces, which bind to and neutralize the conserved inflammation-promoting structures of bacteria and fungi that cause sepsis. These structures provide novel therapeutic targets aimed at both, microbial virulence factors and host inflammatory and immune mediators,

CLOVER Bioanalytical Software is a bioinformatics company specialized in data processing for Bioanalytical Chemistry and Microbial ID and other clinical diagnostics applications using mass spectrometry. Formed by a group of Ph.D. graduates with a wide expertise in business and research, it brings a perfect match to develop cutting-edge software and statistical analysis projects in the biomedical field. They are specialized in mass spectrometry, its clinical applications and mass spectrometry imaging. But their expertise cover many more applications, like medical image processing, univariate and multivariate statistical analysis, and Big Data. They are truly customer-oriented, keeping in mind the goals of their clients and the scalability of the systems. They count with experts in biomedicine, chemistry and biotechnology that speak your own language and understands your needs.

Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a iodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion University by Dr. Dror Seliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications and has undergone extensive preclinical and safety testing over the last few years. The company’s flagship product, GelrinC™,designed for the treatment of articular cartilage lesions, is currently in clinical trials.

Virtual Bodyworks is a company committed to improving lives by harnessing the power of scientifically-proven breakthrough technology. Their company specialises in immersive virtual reality focused on medical and psychological rehabilitation. Founded by scientists world renowned for their work in VR, we offer products that integrate a unique combination of computer science engineering, neuroscience and psychology.

Bioengineering Laboratories (BEL) has been conceived as a young, streamlined and multi-faceted organization able to provide technical knowledge and a twenty year experience in designing, testing and producing innovative medical devices in the bioengineering industry. BEL is a pool of professional professionals able to critically address and re-elaborate the key aspects of a “modern” design in the medical field. The knowledge of the market, the openness to new clinical and surgical techniques, the curiosity towards new technologies, the application of an effective Quality System and the constant updating of the current legislative and regulatory requirements are their basis for engineering dedicated to life.

CyTuVax is a clinical stage vaccine company focused on developing innovative solutions to address significant medical needs. The company collaborates with leading European research institutions to advance its adjuvant technology, which enhances immune responses in both humoral and cellular aspects. This technology can be applied to both prophylactic vaccines targeting viral and bacterial pathogens and therapeutic vaccines for cancer treatment. By utilizing depot-attached cytokines as immune stimulators, CyTuVax's platform aims to improve the efficacy of standard vaccines, reduce the number of required injections, and ultimately place the patient at the center of its vaccine development efforts.

MDxHealth is a molecular diagnostics company focused on developing and commercializing advanced tests for cancer assessment and personalized treatment. The company offers a range of products including ConfirmMDx, a prostate cancer testing solution that addresses false-negative biopsy concerns; SelectMDx, which helps guide repeat biopsies for prostate cancer; and AssureMDx, a noninvasive liquid biopsy test for bladder cancer that assists in decision-making for cystoscopy. Additionally, MDxHealth provides PredictMDx for Glioblastoma, a tissue methylation test that aids in treatment decisions for brain cancer. Founded in 2003 and headquartered in Irvine, California, MDxHealth operates additional offices in Herstal, Belgium, and Nijmegen, the Netherlands. The company generates revenue through clinical laboratory services and the out-licensing of its patented DNA methylation platform and biomarkers, serving markets in the United States and Europe.

Lab-on-Fiber GmbH, based in Halle, Germany, specializes in the development and production of advanced medical laser probes and systems aimed at enhancing minimally invasive surgical procedures. The company offers a range of fiber delivery systems, including surgical and urology fiber probes. By providing optimized radiation profiles and real-time temperature monitoring at the probe surface, Lab-on-Fiber's technology helps surgeons reduce operating times, improve treatment outcomes, and enhance patient safety. Their innovative solutions are designed to streamline laser surgery while minimizing potential complications, positioning Lab-on-Fiber as a key player in the medical technology sector.

Bambi Medical is a MedTech company founded in November 2015 by Sidarto and Fabio Bambang Oetomo, aiming to alleviate pain and stress in pre-term infants while enhancing parent-child bonding. The company specializes in the design, development, and manufacturing of innovative products for Neonatal Intensive Care Units (NICUs) in hospitals. One of its key offerings is a wireless health monitoring device that tracks critical health metrics such as breathing, heart rate, temperature, and electrocardiogram (ECG) without the discomfort associated with traditional adhesive electrodes. This device facilitates maximum skin-to-skin contact between infants and their parents, allowing for effective monitoring of the baby's health while minimizing pain and skin irritation.

Mercurna is a developer of life-changing mRNA medicines. They also develop modular nanomedicines that can be adapted to a multitude of diseases with ease. They built a sustainable business that keeps on providing society with truly valuable medicines. They also provide mRNA medicines particularly suited to the treatment of chronic inflammatory diseases.

RegStem is an early stage biopharmaceutical company repurposing molecules and creating new treatments in the fields of regenerative medicine and more specifically in the areas of rare muscle and blood diseases with high unmet medical needs.

Filterlex Medical Ltd. is a medical device startup focused on the cardiovascular field, specifically developing an advanced embolic protection device aimed at reducing the risk of stroke and other complications during catheter-based structural heart procedures. The company's innovative device utilizes next-generation technology to address the limitations of existing products. It is designed to be securely positioned in the aorta, providing comprehensive embolic protection by deflecting, capturing, and removing embolic particles. This approach enables physicians to enhance patient safety during these complex procedures. Currently, Filterlex is seeking seed funding to further advance its development efforts.

Depixus is a biotechnology company that has developed a novel technology designed for real-time analysis of individual biomolecular interactions at a large scale. Its platform enables comprehensive genome analysis, allowing researchers to examine entire genomic regions quickly and efficiently. This integrated system provides the flexibility to specify the desired level of sequence and epigenetic detail, facilitating the discovery of new biological pathways and the decoding of disease mechanisms. By enhancing the understanding of these processes, Depixus aims to contribute to the development of new precision medicines. The company's focus on advanced DNA and RNA sequencing technologies addresses the limitations of current methods, particularly in achieving single-molecule precision.

Klaria Pharma Holding AB is a Swedish pharmaceutical company that specializes in the development and commercialization of innovative rapid-acting products for managing migraine and cancer-related pain. Utilizing a patented drug delivery platform, the company employs an alginate-based polymer film that adheres to the oral mucosa, enhancing the efficacy of well-established pharmaceuticals. Klaria's approach combines advanced technology with proven medications, offering significant benefits and potential applications for patients. The majority of the company's operations are based in Sweden, where it focuses on improving treatment options for pain management.

Arrhythmia Algorithm S.L. (https://rithmi.com) is a privately held company with the mission to support people to take care of their heart and prevent health problems as the stroke. Their aim is to revolutionize the way Auricular fibrillation is diagnosed through a comfortable, compliant and innovative method. After successfully piloting the prototype version of RITHMI technology, the team can confirm the capability of its breakthrough product to open new markets in Europe with the potential for rapid growth. Rithmi is a pioneer in arrhythmia detection technologies and the leading company in Computational Predictive Care™.

Biprocel is a biotechnological company.

Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.

SamanTree Medical is a swiss innovative medical device company providing a breakthrough imaging solution with the potential to improve patient care and cancer surgery outcome. Based on confocal microscopy, SamanTree Medical’s solution brings accurate and full margin control by the surgeon, in the operating room.

Stayble Therapeutics AB is a clinical-stage pharmaceutical company based in Gothenburg, Sweden, focused on developing an innovative injection treatment for chronic low back pain caused by degenerative disc changes. The company's primary product, STA363, is an intradiscally injected formulation designed for patients who do not experience relief from conventional treatments such as analgesics and physiotherapy. This minimally invasive treatment aims to address the underlying causes of discogenic pain by stabilizing the disc and preventing the leakage of inflammatory mediators. STA363 is administered as a single injection, with the potential for long-lasting effects and minimal rehabilitation requirements. The experienced multidisciplinary team behind Stayble Therapeutics includes renowned researchers and seasoned professionals from the pharmaceutical industry, all dedicated to alleviating the suffering of millions impacted by chronic back pain.

Mirrakoi SA is a Swiss company established in 2018 and is a spin-off from the Swiss Federal Institute of Technology in Lausanne. It specializes in developing computer-aided design software, particularly focused on the medical field. The company's flagship product, Rhino3DMedical, facilitates a seamless workflow that allows users to view, analyze, and segment medical images, ultimately enabling the creation of 3D-printable meshes and CAD models from CT and MRI scans. This proprietary software is designed with a user-friendly interface, making it accessible for orthopedic surgical planning and the production of patient-specific anatomical models. Mirrakoi's innovative technology streamlines the process of generating anatomical 3D prints, enhancing both efficiency and precision in medical applications.

Airofit is a Danish company that offers a specialized training system designed to strengthen the lungs and improve breathing. Originally developed for medical applications to assist patients with respiratory issues such as asthma and bronchitis, Airofit's equipment focuses on training the diaphragm and intercostal muscles. The system gradually increases the workload on the respiratory system, leading to enhanced breathing power and efficiency. While initially aimed at medical patients, Airofit has proven effective for a broader audience, including athletes seeking to boost endurance and respiratory strength, as well as singers and musicians who benefit from improved coordination and sound quality. The company's innovative approach not only enhances respiratory capacity but also helps reduce the reliance on medications for individuals with chronic respiratory conditions.

Abanza Tecnomed provides research and development of instruments and medical devices specialized in biomedical innovation in the field of sports medicine. Abanza Tecnomed is a research and development company of medical instruments and devices, specialized in biomedical innovation in the field of Sports Medicine. With the commitment to develop and offer the latest generation devices to facilitate the work of medical professionals, ABANZA Tecnomed has a multidisciplinary and highly qualified R&D&I team that guarantees the quality of innovations, and a first-class medical advisory board that certifies the precision and safety of the instruments developed.

Oxoprobics microplates provide a powerful tool and biological services based on this technology for obtaining proof of mechanism data, useful as first exploratory assessments, refocusing and adapting new tailored methodologies for its use in cell biology (e.g. mitochondrial inhibition or uncoupling, stimulation or inhibition of oxygen-consuming reactions catalyzed by enzymes, antibiotic resistance, etc.) or Immunology (lymphoproliferation kinetics in whole blood, antigen recognition and sensitivity, etc.).

Pplus Skin Care Limited is a UK-registered company founded in 2014 by Dr Mitra Najafi (MD), a multi award winning cosmetic clinician who has spent several years on R&D and developed the first prototype of Pplus products which provide pain free, none-invasive and more affordable application of PRP. An innovative product tailor made and unique for every individual.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

Cellink is a biotechnology company and one of the first bioink companies in the world. The company leverages its bioink and 3D printing technology to print human organs and tissue models, which potentially can be used in e.g. oncology research, drug testing, and cosmetic testing. The company’s vision is to create the future of medicine by making bioprinting technology as accessible, user-friendly, and high performing as possible. Cellink has offices in Gothenburg, Sweden, and Palo Alto, California, and collaborates with different organizations across the globe.

React4life is an Italian biotech company established in 2016 by Silvia Scaglione and Maurizio Aiello, following over 15 years of research and development. The company focuses on advancing biomedical research through its innovative technology, MIVO® (Multi In Vitro Organ), which represents a next-generation organ-on-a-chip system. This microphysiological platform allows researchers to simulate human biology more accurately in laboratory settings, addressing the limitations of traditional in vitro assays and animal testing. React4life's technology enhances the reliability and predictivity of various applications, including pharmaceutical drug testing, personalized medicine, immuno-oncology therapies, cosmetics, dermatology, and nutraceuticals. By enabling the cultivation of three-dimensional human-like tissues for in vitro testing, React4life aims to improve the effectiveness of laboratory experiments and promote ethical research practices.

Senolytic Therapeutics is a operator of a pharmaceutical company intended to develop medicines and therapeutics for patients affected by age-related diseases. The company's medicines target and eliminate damaged cells, enabling healthcare providers to improve the lives of those affected by diseases associated with aging.

Schepp Medtech GmbH, based in Niklasdorf, Austria, specializes in developing and manufacturing medical devices aimed at supporting patients with gait training needs. The company offers a rehabilitation machine designed for neurological therapy, addressing various conditions including stroke, paraplegia, multiple sclerosis, Parkinson's disease, infantile cerebral palsy, orthopedic and trauma syndromes, immobile geriatric patients, and polio. Additionally, Schepp Medtech is involved in the certification and ongoing support of its medical products within the rehabilitation segment.

Resani specializes in hand sanitizing technology aimed at enhancing hand hygiene compliance and ultimately saving lives. The company has developed a product that integrates an automatic hand sanitizer with a disinfection cartridge and user-monitoring technology. This innovative system not only quantifies hand hygiene compliance but also employs advanced statistical data modeling to provide real-time insights. By visualizing hand hygiene metrics, Resani enables rapid decision-making and fosters a culture of frequent hand sanitization among users. The attractive design of the device encourages regular use, making hand hygiene more accessible, reliable, and sustainable.

AXO Science is dedicated to enhancing public health through the development of innovative diagnostic solutions. The company has created a forensic testing tool that offers multi-parameter diagnostic characterizations. This sophisticated tool features an integrated biochip, which incorporates multiple oligonucleotide probes grafted onto a polymer membrane. As a result, forensic departments and diagnostic enterprises can utilize advanced technologies for molecular-based diagnosis, improving their capabilities in the field of diagnostics.